The Development of Standardized National Head Circumference Growth Charts for Jordanian Children Aged 0–5 Years: A Longitudinal and Cross-Sectional Study
Abstract
Background: Head circumference (HC) is a key indicator of growth and brain development in children, used to identify abnormalities like microcephaly and macrocephaly. While WHO growth standards are widely adopted, they may not account for regional variations due to genetic, environmental, and socio-economic factors. This study aimed to develop and validate national HC growth charts for Jordanian children aged 0–5 years and compare them with WHO standards. Method: This study analyzed 628,456 HC measurements from 250,276 Jordanian children (51.6% boys, 48.4% girls) aged 0–1800 days, using data from the Hakeem program. Only healthy children were included. HC measurements followed international guidelines, and data were analyzed using the Lambda–Mu–Sigma (LMS) statistical method. Percentiles were calculated, and growth patterns were compared with WHO standards. Results: National HC-for-age growth charts were developed for the 3rd, 15th, 50th, 85th, and 97th percentiles. Median percentiles for Jordanian children aligned with WHO standards, but the 3rd percentile was lower, particularly for girls after 840 days. The 97th percentile diverged after 240 days, with larger HC measurements observed in Jordanian children. Conclusions: This study provides the first validated HC growth charts for Jordanian children, addressing the limitations of international standards in reflecting regional variations. These charts offer clinicians and public health professionals a precise tool for…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 250,276 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.